Fast Five Quiz: Liver Disease

B.S. Anand, MD

Disclosures

August 16, 2019

According to the AASLD, the diagnosis of NAFLD requires evidence of hepatic steatosis on imaging or histologic findings, no significant alcohol consumption, no competing etiologies for hepatic steatosis, and no coexisting causes of chronic liver disease. When evaluating a patient with suspected NAFLD, the AASLD recommends that a liver biopsy be considered in the presence of persistently high serum ferritin levels and increased iron saturation. This is particularly true in the context of homozygote or heterozygote C282Y HFE mutations. Liver biopsy should also be considered in patients with suspected NAFLD in whom competing etiologies for HS and the presence and/or severity of coexisting chronic liver diseases cannot be excluded without a liver biopsy.

According to AASLD guidelines, systemic screening of family members diagnosed with NAFLD is not recommended at this time. Routine screening for NAFLD in high-risk groups attending diabetes clinics, obesity clinics, or primary care facilities is also not recommended at this time, owing to the uncertainties surrounding diagnostic tests and treatment options. The long-term benefits and cost-effectiveness of screening are also uncertain.

Read more about NAFLD.

Comments

3090D553-9492-4563-8681-AD288FA52ACE
Comments on Medscape are moderated and should be professional in tone and on topic. You must declare any conflicts of interest related to your comments and responses. Please see our Commenting Guide for further information. We reserve the right to remove posts at our sole discretion.
Post as:

processing....